



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2018-19

May 16, 2019

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE ID: AARTIDRUGS
BSE CODE – 524348

To,
Listing/ Compliance Department
**National Stock Exchange of India
Limited,**
“Exchange Plaza”, Bandra - Kurla
Complex, Bandra (E), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release

Please find enclosed herewith copy of the press release issued by the Company on May 16, 2019.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED


RUSHIKESH DEOLE
COMPANY SECRETARY
ICSI M.No.: A54527





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Press release for Mar'19

In March quarter, company recorded the consolidated quarterly revenue of Rs.464.13 Crores with year-on-year growth of 40.02%. Domestic sales of the API segment grew by approximately 33.96% and exports by 48.57%. Around 63% of the API segment growth was driven by volume increase and rest due to rate variance. Formulation segment revenues grew by around 36.16% on year-on-year basis.

Consolidated EBITDA for the quarter ended March'19 is Rs. 60.9 Crores, up by 6.13% and consolidated profit after tax for the quarter ended March'19 is Rs.27.44 Crores, up by 14.37%. Company was carrying heavier inventory as of Dec'18 end, in expectation of higher March quarter demand. In Dec'18 quarter raw material prices were much higher and hence opening stock of Mar'19 quarter was valued at higher rates. However, raw material prices decreased in later half of the March quarter which led to downward correction in selling prices. Because of first in first out method, raw material consumed for Mar'19 quarter was at much higher rate and hence gross margins of the Company was heavily impacted for the Mar'19 quarter leading to lower operating margins. Due to improved working capital management Company was able to reduce its Debt/Equity ratio to 0.91 as of Mar'19 on standalone basis.

Company recently expanded its anti-diabetic capacity and currently scaling up its production quantities for the same. Further CAPEX would be done to expand few capacities in anti-inflammatory therapeutic category.

FOR AARTI DRUGS LIMITED

Harshit M. Savla

Jt. Managing Director

DIN : 00005340

